Press release November 18, 2026

VibroSense Dynamics receives Notice of Acceptance for its patent application in Australia

VibroSense Dynamics AB (publ) announces that the company has received a Notice of Acceptance from IP Australia, the Australian patent authority, for its patent application relating to the prediction of chemotherapy-induced peripheral neuropathy (CIPN).

The patent protects VibroSense's method for predicting CIPN using low-frequency vibration perception detection (LF-VPD). The method enables early identification of patients at elevated risk of developing nerve damage as a result of chemotherapy, which may support treatment adjustments and improved patient outcomes.

The patent application is based on research conducted by Bo Olde and Toni Speidel at VibroSense Dynamics.

Australia is one of the world's best-funded healthcare markets, with high cancer incidence and a well-established oncology care system. The country has a strong scientific infrastructure and a clear clinical need for better tools for the early detection of treatment side effects. The patent acceptance in Australia creates a strong foundation for future commercialization in the Australian market.

"This is an important step for VibroSense. Having our patent accepted in Australia confirms that our method for CIPN prediction meets high standards and has the potential to make a real difference for cancer patients", says Toni Speidel, CEO of VibroSense Dynamics AB.

For more information, please contact:
Toni Speidel, CEO
VibroSense Dynamics AB (publ)
Phone: +46 40 88 026
Email: info@vibrosense.com
Website: www.vibrosense.com

"The new Gold Standard for reliable detection of nerve damage"

About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (publ) develops and sells medical devices and services to facilitate diagnosis of nerve damage in the hands and feet. The method is based on measuring and quantifying the ability to perceive vibrations applied to the skin at multiple frequencies. The company's customers include diabetes clinics, occupational health providers, hospitals, primary care centers, and researchers.

Our vision is that the company's products shall become a standard tool in all neurological examinations, to detect early signs of sensory changes so that patients and healthcare providers can take preventive action to avoid, reduce, or delay the onset of nerve damage in the hands and feet.